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I.V. ascorbic acid for treatment of apparent rasburicase-induced
methemoglobinemia in a patient with acute kidney injury and
assumed glucose-6-phosphate dehydrogenase deficiency
David J. Reeves, Pharm.D., BCOP
Lindsay M. Saum, Pharm.D., BCPS, CGP
Ruemu Birhiray, M.D.

Abstract
Purpose A case of apparent rasburicase-induced methemoglobinemia and acute kidney injury treated with
i.v. ascorbic acid because of suspected glucose-6-phosphate dehydrogenase (G6PD) deficiency is reported.
Summary A 46-year-old African-American man with a recent diagnosis of multiple myeloma and renal
insufficiency was admitted to the hospital with a cough, hemoptysis, and fatigue. His medical history
included hypertrophic cardiomyopathy, ventricular tachycardia, attention deficit/hyperactivity disorder,
and pleural effusion. No treatments for multiple myeloma were started before hospital admission.
Levofloxacin 750 mg orally daily for possible pneumonia, lenalidomide 10 mg orally daily, and
dexamethasone 20 mg orally weekly were administered. Plasmapheresis was also initiated. Laboratory test
results revealed sustained hyperuricemia, which was believed to be due in part to tumor lysis, and a single
dose of rasburicase 6 mg i.v. was administered. Subsequently, the patient experienced a decrease in oxygen
saturation. Methemoglobinemia was suspected, and the patient’s methemoglobin fraction was found to be
14.5%. The patient developed worsening shortness of breath and a drop in hemoglobin concentration,
consistent with methemoglobinemia and hemolysis. Ascorbic acid 5 g i.v. every 6 hours was initiated for a
total of six doses. Because the patient was assumed to have G6PD deficiency, which was later confirmed,
methylene blue was avoided. Within 24 hours, the patient’s oxygen saturation values and symptoms
improved.
Conclusion A patient with apparent rasburicase-induced methemoglobinemia and acute kidney injury was
treated with i.v. ascorbic acid (5 g every six hours for six doses) because of the possibility, later proved,
that he had G6PD deficiency. The methemoglobinemia resolved without worsening of renal function.

Methemoglobins are characterized by the presence of oxidized heme iron (ferrous iron) and are
formed spontaneously at low concentrations under normal physiological conditions due to the
usual oxidative stressors present in the body.1 Metabolic pathways reduce the heme iron to the
ferric state and thus help maintain the functionality of hemoglobin in oxygen transport. The most
active reducing enzyme in red blood cells is cytochrome b5 reductase, which requires cytochrome
b5 and nicotinamide adenine dinucleotide for activity. Additional reducing mechanisms include
the nonenzymatic substances ascorbic acid and glutathione, as well as nicotinamide adenine
dinucleotide phosphate (NADPH) flavin reductase. Drugs such as rasburicase and dapsone are
known to cause an elevation in methemoglobin—methemoglobinemia—susceptible patients.2,3
Patients with a deficiency of glucose-6-phosphate dehydrogenase (G6PD) are at risk for
methemoglobinemia.
G6PD deficiency occurs most frequently in individuals of African, Asian, Mediterranean, or
Middle Eastern descent.4 Moreover, the mutation responsible for the deficiency is located on the
X chromosome and, therefore, more common in men. In the United States, 1 in 10 AfricanAmerican males have G6PD deficiency.4 G6PD plays an integral role in the hexose
monophosphate shunt, which is the only source of reduced NADPH, a cofactor in the metabolism
of glutathione.5 Oxidants produced by drugs in the presence of G6PD deficiency cannot be reduced
due to the deficiency in glutathione production, and the result is methemoglobinemia. In addition,
the presence of oxidative stress depletes glutathione, which leads to further oxidation and the
formation of Heinz bodies (insoluble hemoglobin cross-links).5,6 Subsequently, red blood cells
become stiff and susceptible to destruction, resulting in hemolysis. In patients without G6PD
deficiency, methylene blue remains the standard of care for the treatment of methemoglobinemia;
however, patients with G6PD deficiency are unable to reduce methylene blue to its active
antioxidant metabolite, leukomethylene blue.7 Moreover, methylene blue in this population can
worsen oxidative stress and potentially worsen hemolysis.4 Although tests for G6PD deficiency
are available, such testing is not feasible for all patients receiving drugs that put them at risk for
methemoglobinemia due to a long delay for test results at some institutions and the urgent nature
of some of the treatments. We report a case of a patient with presumed G6PD deficiency who
developed methemoglobinemia after receiving rasburicase for the treatment of tumor lysis
syndrome.
Case report
A 46-year-old African-American man (weight, 98 kg) with a recent diagnosis of multiple myeloma
and renal insufficiency was admitted to the hospital with a cough, hemoptysis, and fatigue. His
medical history included hypertrophic cardiomyopathy, ventricular tachycardia, attention
deficit/hyperactivity disorder, and pleural effusion for which he had undergone thoracentesis four
days before admission. His outpatient medications included methylphenidate, zolpidem, and
naproxen sodium. No treatments for multiple myeloma were started before hospital admission. His
laboratory test values at hospital admission appear in Table 1. Therapy initiated in the hospital
included levofloxacin 750 mg orally daily for possible pneumonia, lenalidomide 10 mg orally
daily, and dexamethasone 20 mg orally weekly starting on the day of admission. Antimyeloma
treatment was started on admission because multiple presenting symptoms were thought likely due
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to the myeloma. In addition, the patient was scheduled for plasmapheresis every other day for four
to six sessions.
Table 1
Patient’s Laboratory and Other Valuesa

Value
Serum potassium
conc., meq/L
Blood urea nitrogen
conc., mg/dL
Serum creatinine
conc., mg/dL
Uric acid conc.,
mg/dL
Urine output, mL/24
hr
Serum calcium conc.,
mg/dL
Serum phosphate
conc., mg/dL
Serum total bilirubin
conc., mg/dL
Oxygen saturation, %
Hemoglobin conc.,
g/dL
Serum free light
chains, κ/λ ratio
Methemoglobin
fraction, %
•
•
•
•

2
4.6

Hospital Day
3
4
5
6
4.2 5.0 4.5 3.6

7
3.9

8
3.9

68

74

46

61

Institution’s
Normal Range
3.5–5.1

1
5.5

8–26

56

0.8–1.5

4.86

3.89 4.05 4.38 5.36 3.69 3.29

4.0

<8

14.1

12.3 NM

6.2

NA

1300 1150 350 2775 5830 3840 2350 1650

95

1.5

123

1.7

68

3.0

3.2

8.4–10.5

10.0

9.1

9.2

9.2

9.4

9.1

9.0

9.1

2.5–4.7

5.7

5.8

4.4

4.5

5.9

3.5

3.8

NM

0.2–1.2

NM

NM NM 11.4

7.7

NM

3.3

NM

NA

97–
100b
8.4

NM 75–
80c
7.6 8.3

83–
98d
5.7

95–
100d
7.2

95–
98b
7.5

98– NM
100b
9.5 9.8

5948.09 NM NM NM

NM

NM

NM NM

1.2

0.5

NM

11.6–15.2
0.26–1.65
<1.2

NM

NM 14.5

8.1

0.5

a Day 1 was the day of admission. Rasburicase was given on day 2, and ascorbic acid was started on day 4.
NM = not measured, NA = not available.
b On room air.
c On oxygen 15 L/min via nonrebreather mask.
d On oxygen 6 L/min via nasal cannula.
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KEY POINTS
•
•
•

Methemoglobinemia and hemolysis can occur after rasburicase
administration, particularly in patients with G6PD deficiency.
Patients with G6PD deficiency should not receive methylene blue to treat
methemoglobinemia.
Ascorbic acid may be effective in the treatment of methemoglobinemia and
appears safe in the setting of renal dysfunction at a dose of 5 g i.v. every six
hours.

On hospital day 2, laboratory test results revealed sustained hyperuricemia, which was believed to
be due in part to tumor lysis, given the patient’s myeloma burden, and worsened by renal failure;
therefore, a single dose of rasburicase 6 mg i.v. was administered. At this time, the benefits of
treating this oncological emergency outweighed the risks of administering rasburicase in a patient
whose G6PD status was unknown. In addition, the turnaround time for G6PD test results was three
to four days. During the morning of hospital day 3, the patient developed a decrease in oxygen
saturation and was placed on a nonrebreather mask with 15 L/min of supplemental oxygen, despite
being asymptomatic. Methemoglobinemia was suspected, and the patient’s methemoglobin
fraction was found to be 14.5% (normal range, 0.0–1.2%).
On day 4, the patient developed worsening shortness of breath and a drop in hemoglobin
concentration, consistent with methemoglobinemia and hemolysis. At this time, the patient
received three units of blood, and treatment was started with ascorbic acid 5 g i.v. every 6 hours
for a total of six doses. The patient was assumed to have G6PD deficiency based on the
development of methemoglobinemia after rasburicase and his race; consequently, methylene blue
was avoided. Within 24 hours of initiating ascorbic acid, the patient’s oxygen saturation values
and symptoms improved. The patient received two sessions of hemodialysis for volume overload
on hospital days 5 and 6 and was given a unit of blood on each of those two days; reticulocyte
counts were not performed during that time. Moreover, his serum creatinine concentration
remained relatively stable, and his urine output was satisfactory throughout the majority of the
hospital stay. Follow-up serum creatinine values after discharge ranged from 2.86 to 7.11 mg/dL.
A blood sample collected on hospital day 7 for measurement of G6PD yielded a result in the low
normal range, 6.0 units per gram of hemoglobin (normal range, 4.6–13.5 units/g hemoglobin). A
recheck one month later yielded a G6PD result of 5.3 units/g hemoglobin, but results may be
unreliable in the setting of recent blood transfusions or elevated reticulocyte counts, which were
likely a factor in this case.
Discussion
In patients with G6PD deficiency and methemoglobinemia, the risk of hemolysis after methylene
blue administration points to the need for additional treatment options. Non-pharmacologic
4

management with hyperbaric oxygen and exchange transfusions have been used for patients with
methemoglobinemia who were refractory to methylene blue but not as first-line therapy.8 This
leaves a significant gap in therapy for a select patient population.
Case reports of rasburicase-induced methemoglobinemia have been published, but the majority of
those patients receiving treatment, besides transfusion, received methylene blue.9–14 As previously
mentioned, methylene blue is not the ideal option in a patient with suspected G6PD deficiency. To
date, there is only one published report of using ascorbic acid in rasburicase-induced
methemoglobinemia.9 The patient was a 52-year-old African-American man with refractory
multiple myeloma. The patient met the criteria for tumor lysis syndrome and acute kidney injury
before therapy initiation and received rasburicase 6 mg i.v. on the first day of therapy with
cyclophosphamide and methylprednisolone. Starting on the second day of therapy, the patient
showed signs of hypoxemia (oxygen saturation as measured by pulse oximetry [Spo2], 75%)
without clinical symptoms of respiratory distress, and his methemoglobin fraction was
subsequently found to be 12.9%. Ascorbic acid 1 g orally once daily was initiated instead of
methylene blue due to the unknown nature of the patient’s G6PD status. By day 4 of therapy, the
patient’s methemoglobinemia had resolved, with a normal Spo2 (>95%) and a much lower
methemoglobin fraction (<2%). On day 3 of therapy, he developed hemolytic anemia thought to
be due to G6PD deficiency, a recently discovered condition, and required a total of 8 units of
packed red blood cells.
The proposed mechanism of ascorbic acid in the treatment of methemoglobinemia is the reduction
of the oxidative stress common with this condition.15 Efficacy in reducing oxidative stress was
found in patients with hemodialysis-induced methemoglobinemia who received ascorbic acid 1 g
i.v. before each hemodialysis session for two months.16 A peak serum ascorbic acid concentration
of at least 10 mmol/L must be achieved to prevent further formation of methemoglobin.17 An oral
ascorbic acid dose of 1.25 g achieves a mean serum concentration of 0.134 mmol/L, and
extrapolation to a maximally tolerated oral dosage of 3 g every four hours would result in a peak
concentration of 2.2 mmol/L.18 Peak serum ascorbic acid concentrations are estimated to reach
13.4 mmol/L after 50 g of ascorbic acid is given i.v. The concern with administering high doses
of ascorbic acid to achieve these concentrations is the increased risk of hyperoxalate-induced
nephrotoxicity.19 One of the metabolites of ascorbic acid is oxalate. The high doses of ascorbic
acid may lead to increased calcium oxalate crystallization in the renal tubules and epithelium,
causing acute tubular injury.
There are limited published data regarding the successful treatment of methemoglobinemia with
high-dose ascorbic acid. One case report described the use of high-dose ascorbic acid for dapsoneinduced methemoglobinemia.15 The patient was an 85-year-old Korean woman who ingested
seven tablets of dapsone and arrived at the emergency room with decreased mental status and
cyanosis. The patient’s mental status, cyanosis, and methemoglobin concentration continued to
worsen 7 hours after her arrival at the hospital, with a peak methemoglobin fraction of 64.4%.
Methylene blue was unavailable at the time of treatment, so ascorbic acid 10 g i.v. was
administered. The patient’s methemoglobin fraction improved over 15 hours to 38%; however,
after a second dose of ascorbic acid 10 g i.v., the patient’s methemoglobin fraction increased to
5

46.9%. An additional dose of ascorbic acid 10 g i.v. was administered, with slow improvement in
both her symptoms and laboratory test values (methemoglobin fraction, 21.5%). After the first 30
g of ascorbic acid was administered, an additional five doses of ascorbic acid 10 g i.v. every 6
hours was administered, for a total of 80 g. Fifty-four hours into the patient’s care, the last dose of
ascorbic acid was given, and the patient’s methemoglobin fraction was 12.2% and continued to
decline to normal limits within 130 hours after her arrival at the hospital. The patient’s renal
function remained stable throughout the duration of ascorbic acid treatment and hospitalization.
Compared with the patient with dapsone-induced methemoglobinemia, our patient received a total
of 30 g of ascorbic acid over a 36-hour period—a more conservative dosage due to the patient’s
baseline renal dysfunction. While our patient’s peak methemoglobin fraction (14.5%) was not as
high as that in the dapsone patient case (64.4%), normalization of laboratory values was achieved
within a shorter time frame (2 days versus 5.5 days). Ascorbic acid therapy in our patient was safe,
as demonstrated by stability in the serum creatinine and blood urea nitrogen concentrations and
urine output.
Conclusion
A patient with apparent rasburicase-induced methemoglobinemia and acute kidney injury was
treated with i.v. ascorbic acid (5 g every six hours for six doses) because of the possibility, later
proved, that he had G6PD deficiency. The methemoglobinemia resolved without worsening of
renal function.
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